-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
Research & Education
How GLP-1 medications work is more complex than the familiar phrase “they slow the stomach.” These prescription medicines imitate or extend signaling related to glucagon-like peptide-1, a hormone involved in appetite, glucose regulation and communication between the digestive system and brain.
GLP-1 is an incretin hormone released after eating. Native GLP-1 is short-lived, but pharmaceutical GLP-1 receptor agonists are designed to activate the same receptor for longer. Tirzepatide is different: it activates both GIP and GLP-1 receptors.
Clinical research points to several interacting pathways. GLP-1 receptor activity can increase feelings of fullness, reduce hunger and influence brain networks involved in food intake. It can also delay gastric emptying, particularly during earlier treatment, and support glucose-dependent insulin release while reducing glucagon secretion. No single pathway completely explains the weight changes observed in trials.
No. Gastric emptying is relevant, but its effect differs among agents and may diminish with continued exposure. Research also supports central appetite and satiety mechanisms. Claims that one simple mechanism explains every response go beyond the evidence.
Trials report averages, while individual responses vary. Differences may reflect the medication studied, adherence, tolerability, baseline health, concomitant medicines, nutrition, activity, sleep and biology. A result seen in one participant cannot be promised for another.
No. They differ in receptor targets, approved indications, dosing schedules, trial populations and safety information.
Major weight-management trials generally studied medication alongside nutrition and physical-activity interventions. The evidence should be interpreted in that context.
No. Research-use-only materials are not FDA-approved medicines and must not be used in people.
